Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ibuprofen intravenous - Cumberland Pharmaceuticals

Drug Profile

Ibuprofen intravenous - Cumberland Pharmaceuticals

Alternative Names: Amelior; Caldolor; Ibuprofen injection

Latest Information Update: 22 May 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cumberland Pharmaceuticals
  • Developer Al-Nabil; Alveda Pharma; Cumberland Pharmaceuticals; DB Pharm Korea; GerminMED; Grifols; Piramal Critical Care; PT SOHO Industri Pharmasi; PT. ETHICA Industri Farmasi; Sandor Medicaids; Seqirus
  • Class Amines; Analgesics; Antipyretics; Antirheumatics; Nonsteroidal anti-inflammatories; Phenylpropionates; Small molecules
  • Mechanism of Action Cyclooxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Fever; Pain

Most Recent Events

  • 15 May 2023 US FDA approves Ibuprofen intravenous for infants aged three months to six months of age for treatment of Pain and Fever (IV) in USA
  • 10 Mar 2023 Cumberland Pharmaceuticals and PiSA Pharmaceuticals agree to co-promote Caldolor in Mexico fornon-narcotic pain relief
  • 28 Feb 2023 No recent reports of development identified for clinical-Phase-Unknown development in Fever(In neonates) in USA (IV, Injection)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top